pharma.be is the voice of the innovative Belgian - human and veterinary medicine - pharmaceutical industry. As interest group it represents 130 both small and large innovative pharmaceutical and biotech companies and is the centre of excellence for the industry. pharma.be’s member companies are a major contributor to the Belgian economy. They supply 80 percent of all medicines used in Belgium and have more than 42000 employees. pharma.be is recognised by the government as the association to negotiate on behalf of the innovative biopharmaceutical industry with the Minister of Health, the Minister of Economy, and national bodies such as the National Institute for Health and Disability Insurance (RIZIV/INAMI) and the Federal Agency for Medicines and Health Products (FAGG/AFMPS). Working at the heart of the policy development and decision-making, the aim of pharma.be is to ensure that patients can benefit from the latest and most advanced medicines. Come and learn more on how exactly pharma.be works to defend the interests of the pharma industry in Belgium during this face-to-face lunchmeeting.
During this session, we will tackle the required departmental (inter)actions for ensuring full GxP compliance. The Marketing Authorization Holder’s responsibilities will be highlighted within the legal framework of the different good practice guidelines (GMP, GDP, GVP…).
We are very excited to welcome you this fall to our CLINICAL CONFERENCE - formerly known as the ACRP EUROPEAN CONFERENCE - on October 20, 2022 at the Park Inn by Radisson Brussels Airport.